Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-10

AUTHORS

Jennifer R. Schroeder, Karran A. Phillips, David H. Epstein, Michelle L. Jobes, Melody A. Furnari, Ashley P. Kennedy, Markus Heilig, Kenzie L. Preston

ABSTRACT

BACKGROUND: Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines. METHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4 mg/day), then randomized to receive oral pioglitazone (up to 45 mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines. RESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r = 0.70, p = 0.038) and plasma (r = 0.77, p = 0.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended. CONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165. More... »

PAGES

2957-2966

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5

DOI

http://dx.doi.org/10.1007/s00213-018-4986-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106008490

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30079432


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Johns Hopkins Bayview Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.411940.9", 
          "name": [
            "Johns Hopkins Bayview Medical Center, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroeder", 
        "givenName": "Jennifer R.", 
        "id": "sg:person.0737140614.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737140614.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phillips", 
        "givenName": "Karran A.", 
        "id": "sg:person.01102463545.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102463545.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Epstein", 
        "givenName": "David H.", 
        "id": "sg:person.01352571246.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352571246.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jobes", 
        "givenName": "Michelle L.", 
        "id": "sg:person.01303364144.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303364144.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furnari", 
        "givenName": "Melody A.", 
        "id": "sg:person.0646122646.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646122646.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kennedy", 
        "givenName": "Ashley P.", 
        "id": "sg:person.01146316617.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146316617.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Link\u00f6ping University", 
          "id": "https://www.grid.ac/institutes/grid.5640.7", 
          "name": [
            "Center for Social and Affective Neuroscience, IKE, Link\u00f6ping Univ, 58183, Link\u00f6ping, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heilig", 
        "givenName": "Markus", 
        "id": "sg:person.01310670153.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310670153.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Preston", 
        "givenName": "Kenzie L.", 
        "id": "sg:person.0710216340.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710216340.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/adb.12471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003181460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/adb.12471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003181460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004311066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.biopsych.2010.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008080755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00952998709001515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009252117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12367", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012437820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00210-014-0996-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012643033", 
          "https://doi.org/10.1007/s00210-014-0996-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.npp.1301213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013042291", 
          "https://doi.org/10.1038/sj.npp.1301213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.npp.1301213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013042291", 
          "https://doi.org/10.1038/sj.npp.1301213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archpsyc.1985.01790340041006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020424635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamainternmed.2014.5302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020428139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.med.53.082901.104018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024565972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.brainres.2012.12.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028235225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.physbeh.2015.10.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030367467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbi.2008.09.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031591782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1100/tsw.2007.230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035564279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tips.2009.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037523582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbr.2009.09.034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038519026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbr.2008.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039814960"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040088953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02791072.2003.10400007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048705737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbi.2009.01.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051963937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0033-1364035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057304351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/etm.2016.3979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071504896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075026057", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/add.13868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085453121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pbb.2017.10.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092180260"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10", 
    "datePublishedReg": "2018-10-01", 
    "description": "BACKGROUND: Preliminary evidence suggested that the PPAR\u03b3 agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines.\nMETHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4\u00a0mg/day), then randomized to receive oral pioglitazone (up to 45\u00a0mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines.\nRESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r\u2009=\u20090.70, p\u2009=\u20090.038) and plasma (r\u2009=\u20090.77, p\u2009=\u20090.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended.\nCONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal.\nTRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00213-018-4986-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2715425", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1085440", 
        "issn": [
          "0033-3158", 
          "1432-2072"
        ], 
        "name": "Psychopharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "235"
      }
    ], 
    "name": "Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder", 
    "pagination": "2957-2966", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b218ac4d3bdc06e6a0f16732334d35d5485bd84bf28689b82873f25e2f571b83"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30079432"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7608025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00213-018-4986-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106008490"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00213-018-4986-5", 
      "https://app.dimensions.ai/details/publication/pub.1106008490"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000573.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00213-018-4986-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'


 

This table displays all metadata directly associated to this object as RDF triples.

206 TRIPLES      21 PREDICATES      55 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00213-018-4986-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N17ef23e8d2a8471c88120484609fec33
4 schema:citation sg:pub.10.1007/s00210-014-0996-y
5 sg:pub.10.1007/s00213-016-4452-1
6 sg:pub.10.1038/sj.npp.1301213
7 https://app.dimensions.ai/details/publication/pub.1075026057
8 https://doi.org/10.1001/archpsyc.1985.01790340041006
9 https://doi.org/10.1001/jamainternmed.2014.5302
10 https://doi.org/10.1016/j.bbi.2008.09.012
11 https://doi.org/10.1016/j.bbi.2009.01.014
12 https://doi.org/10.1016/j.bbr.2008.10.010
13 https://doi.org/10.1016/j.bbr.2009.09.034
14 https://doi.org/10.1016/j.biopsych.2010.12.010
15 https://doi.org/10.1016/j.brainres.2012.12.035
16 https://doi.org/10.1016/j.pbb.2017.10.002
17 https://doi.org/10.1016/j.physbeh.2015.10.006
18 https://doi.org/10.1016/j.tips.2009.08.002
19 https://doi.org/10.1055/s-0033-1364035
20 https://doi.org/10.1080/02791072.2003.10400007
21 https://doi.org/10.1100/tsw.2007.230
22 https://doi.org/10.1111/acer.12091
23 https://doi.org/10.1111/acer.12367
24 https://doi.org/10.1111/acer.12610
25 https://doi.org/10.1111/adb.12471
26 https://doi.org/10.1111/add.13868
27 https://doi.org/10.1146/annurev.med.53.082901.104018
28 https://doi.org/10.3109/00952998709001515
29 https://doi.org/10.3892/etm.2016.3979
30 schema:datePublished 2018-10
31 schema:datePublishedReg 2018-10-01
32 schema:description BACKGROUND: Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines. METHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4 mg/day), then randomized to receive oral pioglitazone (up to 45 mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines. RESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r = 0.70, p = 0.038) and plasma (r = 0.77, p = 0.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended. CONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N2df504b6892945a09077b34256a66fb2
37 N708d88fa630a43dda95c49a7b0a8c50a
38 sg:journal.1085440
39 schema:name Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder
40 schema:pagination 2957-2966
41 schema:productId N322add4d7b9b4e55b4eafbef01d92b9c
42 N47294a039ab34335bda4f860283e7c30
43 N5d5e33d1e6d24102839b1a49f1e883a0
44 N9cf365ff478943528171f49c7bc3ba56
45 Nafdc03b84be74fe589b70e51f720fc74
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106008490
47 https://doi.org/10.1007/s00213-018-4986-5
48 schema:sdDatePublished 2019-04-10T18:29
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher N72ca977c2cde4a928b03b58c8f1a22bf
51 schema:url https://link.springer.com/10.1007%2Fs00213-018-4986-5
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N096be745308a4956893eca4abe969a8e rdf:first sg:person.0646122646.72
56 rdf:rest Nb3925a5d930f41a3a9fd6a3bc7d711a0
57 N17ef23e8d2a8471c88120484609fec33 rdf:first sg:person.0737140614.98
58 rdf:rest Nabb5bf7009b048eb8efbdd69231b92da
59 N2df504b6892945a09077b34256a66fb2 schema:issueNumber 10
60 rdf:type schema:PublicationIssue
61 N30311b82295d4cd6ad80f5fe2a274866 rdf:first sg:person.0710216340.36
62 rdf:rest rdf:nil
63 N322add4d7b9b4e55b4eafbef01d92b9c schema:name dimensions_id
64 schema:value pub.1106008490
65 rdf:type schema:PropertyValue
66 N382913d4e9694279b546378d2287b5ce rdf:first sg:person.01310670153.54
67 rdf:rest N30311b82295d4cd6ad80f5fe2a274866
68 N47294a039ab34335bda4f860283e7c30 schema:name doi
69 schema:value 10.1007/s00213-018-4986-5
70 rdf:type schema:PropertyValue
71 N5d5e33d1e6d24102839b1a49f1e883a0 schema:name readcube_id
72 schema:value b218ac4d3bdc06e6a0f16732334d35d5485bd84bf28689b82873f25e2f571b83
73 rdf:type schema:PropertyValue
74 N708d88fa630a43dda95c49a7b0a8c50a schema:volumeNumber 235
75 rdf:type schema:PublicationVolume
76 N72ca977c2cde4a928b03b58c8f1a22bf schema:name Springer Nature - SN SciGraph project
77 rdf:type schema:Organization
78 N9cf365ff478943528171f49c7bc3ba56 schema:name pubmed_id
79 schema:value 30079432
80 rdf:type schema:PropertyValue
81 Nabb5bf7009b048eb8efbdd69231b92da rdf:first sg:person.01102463545.22
82 rdf:rest Nee8df10d127d4005b9977136aa2726be
83 Nafdc03b84be74fe589b70e51f720fc74 schema:name nlm_unique_id
84 schema:value 7608025
85 rdf:type schema:PropertyValue
86 Nb3925a5d930f41a3a9fd6a3bc7d711a0 rdf:first sg:person.01146316617.51
87 rdf:rest N382913d4e9694279b546378d2287b5ce
88 Nc615d5c366bd4658a27949d5bf509205 rdf:first sg:person.01303364144.10
89 rdf:rest N096be745308a4956893eca4abe969a8e
90 Nee8df10d127d4005b9977136aa2726be rdf:first sg:person.01352571246.35
91 rdf:rest Nc615d5c366bd4658a27949d5bf509205
92 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
93 schema:name Medical and Health Sciences
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
96 schema:name Clinical Sciences
97 rdf:type schema:DefinedTerm
98 sg:grant.2715425 http://pending.schema.org/fundedItem sg:pub.10.1007/s00213-018-4986-5
99 rdf:type schema:MonetaryGrant
100 sg:journal.1085440 schema:issn 0033-3158
101 1432-2072
102 schema:name Psychopharmacology
103 rdf:type schema:Periodical
104 sg:person.01102463545.22 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
105 schema:familyName Phillips
106 schema:givenName Karran A.
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102463545.22
108 rdf:type schema:Person
109 sg:person.01146316617.51 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
110 schema:familyName Kennedy
111 schema:givenName Ashley P.
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146316617.51
113 rdf:type schema:Person
114 sg:person.01303364144.10 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
115 schema:familyName Jobes
116 schema:givenName Michelle L.
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303364144.10
118 rdf:type schema:Person
119 sg:person.01310670153.54 schema:affiliation https://www.grid.ac/institutes/grid.5640.7
120 schema:familyName Heilig
121 schema:givenName Markus
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310670153.54
123 rdf:type schema:Person
124 sg:person.01352571246.35 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
125 schema:familyName Epstein
126 schema:givenName David H.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352571246.35
128 rdf:type schema:Person
129 sg:person.0646122646.72 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
130 schema:familyName Furnari
131 schema:givenName Melody A.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646122646.72
133 rdf:type schema:Person
134 sg:person.0710216340.36 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
135 schema:familyName Preston
136 schema:givenName Kenzie L.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710216340.36
138 rdf:type schema:Person
139 sg:person.0737140614.98 schema:affiliation https://www.grid.ac/institutes/grid.411940.9
140 schema:familyName Schroeder
141 schema:givenName Jennifer R.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737140614.98
143 rdf:type schema:Person
144 sg:pub.10.1007/s00210-014-0996-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1012643033
145 https://doi.org/10.1007/s00210-014-0996-y
146 rdf:type schema:CreativeWork
147 sg:pub.10.1007/s00213-016-4452-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047185141
148 https://doi.org/10.1007/s00213-016-4452-1
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/sj.npp.1301213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013042291
151 https://doi.org/10.1038/sj.npp.1301213
152 rdf:type schema:CreativeWork
153 https://app.dimensions.ai/details/publication/pub.1075026057 schema:CreativeWork
154 https://doi.org/10.1001/archpsyc.1985.01790340041006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020424635
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1001/jamainternmed.2014.5302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020428139
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.bbi.2008.09.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031591782
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.bbi.2009.01.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051963937
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.bbr.2008.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039814960
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.bbr.2009.09.034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038519026
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.biopsych.2010.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008080755
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.brainres.2012.12.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028235225
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.pbb.2017.10.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092180260
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/j.physbeh.2015.10.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030367467
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.tips.2009.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037523582
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1055/s-0033-1364035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057304351
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1080/02791072.2003.10400007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048705737
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1100/tsw.2007.230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035564279
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1111/acer.12091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004311066
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1111/acer.12367 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012437820
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1111/acer.12610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040088953
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1111/adb.12471 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003181460
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1111/add.13868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085453121
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1146/annurev.med.53.082901.104018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024565972
193 rdf:type schema:CreativeWork
194 https://doi.org/10.3109/00952998709001515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009252117
195 rdf:type schema:CreativeWork
196 https://doi.org/10.3892/etm.2016.3979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071504896
197 rdf:type schema:CreativeWork
198 https://www.grid.ac/institutes/grid.411940.9 schema:alternateName Johns Hopkins Bayview Medical Center
199 schema:name Johns Hopkins Bayview Medical Center, 21224, Baltimore, MD, USA
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.420090.f schema:alternateName National Institute on Drug Abuse
202 schema:name National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA
203 rdf:type schema:Organization
204 https://www.grid.ac/institutes/grid.5640.7 schema:alternateName Linköping University
205 schema:name Center for Social and Affective Neuroscience, IKE, Linköping Univ, 58183, Linköping, Sweden
206 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...